1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Castle Biosciences, Inc.

Castle Biosciences, Inc.

CSTL
Castle Biosciences, Inc.US flagNASDAQ Global Market
35.19
USD
+0.31
- -
1.08BMarket Cap

Total Valuation

Castle Biosciences, Inc. carries a market capitalization of 1.08B, placing it among publicly traded companies globally. Its enterprise value stands at 497.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.08B
Enterprise Value497.47M

Share Statistics

Castle Biosciences, Inc. currently has 30.51M shares outstanding.

Shares Outstanding30.51M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.98, and the price-to-book ratio stands at 1.55.

PE RatioN/A
PS Ratio1.98
PB Ratio1.55
P/TBV Ratio1.94
P/FCF Ratio8.25
P/OCF Ratio16.60

Enterprise Valuation

On an enterprise value basis, Castle Biosciences, Inc. trades at an EV/EBITDA multiple of 52.83 and an EV/FCF ratio of 5.78.

EV / Sales1.39
EV / EBITDA52.83
EV / EBITN/A
EV / FCF5.78

Financial Position

Castle Biosciences, Inc. maintains a current ratio of 6.04, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.80, indicating elevated leverage, while an interest coverage ratio of -44.04 demonstrates limited ability to service its debt obligations.

Current Ratio6.04
Quick Ratio5.58
Debt / Equity7.80
Debt / EBITDA-2.22
Interest Coverage-44.04

Financial Efficiency

Return on Equity (ROE)-4.20
Return on Assets (ROA)-3.51
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover8.58

Taxes

Income Tax212,000.00
Effective Tax RateN/A

Stock Price Statistics

Castle Biosciences, Inc.'s stock has gained approximately 55.22717% over the past 52 weeks. The 50-day moving average sits at 30.78, while the 200-day moving average is 29.19.

Beta (5Y)N/A
52-Week Price Change55.22717%
50-Day Moving Average30.78
200-Day Moving Average29.19
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Castle Biosciences, Inc. generated 357.28M in revenue and converted that into -19.41M in net income, yielding earnings per share of -0.65. EBITDA reached -16.52M, while operating income came in at -32.11M.

Revenue357.28M
Gross Profit276.03M
Operating Income-32.11M
Pretax Income-19.20M
Net Income-19.41M
EBITDA-16.52M
EBIT-32.11M
Earnings Per Share (EPS)-0.65

Balance Sheet

Castle Biosciences, Inc. holds 266.81M in cash and equivalents against 36.65M in total debt, resulting in a net debt position of -52.04M. Total book value stands at 470.03M, with working capital of 284.59M providing operational flexibility.

Cash & Cash Equivalents266.81M
Total Debt36.65M
Net Debt-52.04M
Equity (Book Value)470.03M
Book Value Per Share15.41
Working Capital284.59M

Cash Flow

Castle Biosciences, Inc. produced 42.63M in operating cash flow over the past twelve months. After subtracting -43.12M in capital expenditures, free cash flow totaled -489,000.00 - equivalent to -0.02 per share.

Operating Cash Flow42.63M
Capital Expenditures-43.12M
Free Cash Flow-489,000.00
FCF Per Share-0.02

Margins

Castle Biosciences, Inc. operates with a gross margin of 77.26, reflecting its pricing power and cost economics. The operating margin of -8.99 and net profit margin of -5.43 provide insight into operational efficiency.

Gross Margin77.26
Operating Margin-8.99
Pretax Margin-5.37
Profit Margin-5.43
EBITDA Margin-4.62

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield1.57
FCF Yield12.12

Scores

Castle Biosciences, Inc. posts an Altman Z-Score of 5.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.34